3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
144
Carcinoma, Non-Small-Cell Lung
51
Carcinoma, Transitional Cell
50
Melanoma
46
Urinary Bladder Neoplasms
42
Prostatic Neoplasms
32
Kidney Neoplasms
29
Neoplasm Metastasis
27
Colorectal Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
21
Carcinoma, Hepatocellular
20
Triple Negative Breast Neoplasms
15
Neoplasms
15
Stomach Neoplasms
14
Ovarian Neoplasms
14
Clear-cell metastatic renal cell carcinoma
14
Lung Neoplasms
13
Uterine Cervical Neoplasms
12
Carcinoma, Merkel Cell
11
Small Cell Lung Carcinoma
9
Pancreatic Neoplasms
9
Head and Neck Neoplasms
8
Esophageal Neoplasms
7
Breast Neoplasms
7
Urethral Neoplasms
6
Endometrial Neoplasms
6
Cholangiocarcinoma
6
Urogenital Neoplasms
5
Skin Neoplasms
5
Recurrence
5
Interventions
belzutifan
2
Everolimus
2
Blood Specimen Collection
2
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Sunitinib
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
Nivolumab
×
Genitourinary
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled